Journal of Clinical Oncology
Articles in this Issue
Avidity engineered multifunctional antibodies for stimulation and orchestration of innate and adaptive immune cells in tumor tissues.
8558 Background: Antibodies and ADCs are mainstays in the treatment of cancer. However, given difficulties in achieving a deep and sustained response, sig...
Biologics in the treatment of immune-related adverse events: A systematic review.
e14650 Background: Immune-related adverse events (irAEs) are frequently reported among oncology patients undergoing immune-checkpoint inhibitor (ICI) ther...
Regional node recurrence after sentinel lymph node biopsy for ycN0 patients treated with primary chemotherapy in cT1-3N1M0 breast cancer (second report from SHARE study).
576 Background: Axillary management after sentinel lymph node biopsy (SLNB) is still debated for clinically node-positive breast cancer (BC) patients trea...
Efficacy and safety of pralsetinib in patients with advanced <i>RET</i> -fusion-positive NSCLC: Final data from the phase 1/2 ARROW study.
8644 Background: RET fusions are targetable oncogenic drivers in 1-2% of non-small cell lung cancers (NSCLC). ARROW (NCT03037385) study result...
Progression-free survival in control arms of clinical trials: Analysis of FDA cancer drug approvals between 2014 and 2023.
11031 Background: FDA regularly approves new cancer drugs based on the results of surrogate endpoints, often using expedited programs. When assessing the...
A monocentric real-word experience of CT-IO combination in advanced BTC.
e16247 Background: Biliary tract neoplasms are very aggressive, but new frontiers of treatment are in course of developing for advanced disease. One of th...
Effect of AdAPT-001 on checkpoint inhibitor resistance in solid tumors.
2618 Background: Checkpoint inhibitors (CIs) have revolutionized cancer treatment, but most patients do not respond to them because of primary or secondar...
MagnetisMM-32: A phase 3 randomized study of elranatamab vs EPd, PVd, or Kd in patients with relapsed or refractory multiple myeloma (RRMM) and prior anti-CD38–directed therapy.
TPS7568 Background: Elranatamab (ELRA), a BCMA-CD3 bispecific antibody, has shown efficacy and manageable safety as a monotherapy in patients with RRMM. T...
Integration of a podcast curriculum (PC) to improve hematology oncology fellow (HOF) knowledge: A multi-center cluster randomized control trial.
9001 Background: Medical podcasts are widely used as learning resources, yet their integration into fellowship curricula remains unstudied. We present the...
Travel impacts for patients with cancer living in the rural Mountain West.
e13533 Background: Limited oncology clinical care resources in rural and frontier areas affect the quality of cancer care and outcomes. Drive times to a c...
A SEER stat analysis of epidemiological and anatomical prognostic indicators of mesothelioma.
e20091 Background: Mesothelioma is a rare malignancy with a historically poor prognosis. The development is mostly related to asbestos exposure. However r...
Retrospective registry for uveal melanoma in Lebanon: 10-year single-center experience of a major referral center in the Middle East and North Africa region.
e21603 Background: Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, comprising 80% of ocular melanomas. Despite advances i...
Sarcopenia and postoperative outcomes in patients with peritoneal carcinomatosis undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
e15604 Background: Multiple primary neoplasms spread to the peritoneal cavity, previously considered an untreatable and terminal condition. Cytoreductive...
Plasma-based next generation sequencing in advanced non-small cell lung cancer (NSCLC): Significance in diagnosis and treatment.
e20635 Background: Next generation sequencing (NGS) is recommended in the evaluation of advanced NSCLC prior to treatment. However, up to 20% of tissue bi...
Utilization of large language models to facilitate guideline-directed therapy of genitourinary cancer screening and primary workup.
e13705 Background: The rise of large language models (LLMs) offers a unique opportunity to streamline healthcare and simplify medical decision-making. The...
A phase I clinical trial on combined (neo-)adjuvant intravenous plus intracranial administration of ipilimumab and nivolumab in recurrent glioblastoma (NEO-GLITIPNI).
2049 Background: Intravenous (IV) administration of ipilimumab (IPI) and nivolumab (NIVO) has shown limited activity in recurrent glioblastoma (rGBM). Int...
A real-world study of nab-paclitaxel-based chemotherapy with or without PD-1/PD-L1 blockade in second-line treatment of advanced biliary tract cancer.
e16242 Background: Nab-paclitaxel has shown promising antitumor activity in biliary tract cancer (BTC). Although gemcitabine-cisplatin combined with immun...
Phase 2 study of axitinib + nivolumab in mucosal melanoma with pilot addition of stereotactic body radiotherapy or ipilimumab in select progressors.
9555 Background: Mucosal melanoma (MM) is an aggressive subtype of melanoma with distinct biology, and outcomes in advanced disease are inferior compared...
Rare ALK: Clinical characteristics and efficacy of targeted therapy in NSCLC with ALK fusions other than EML4::ALK.
8625 Background: More than 90% of ALK rearrangements in NSCLC lead to recurrent fusions with EML4. The remainder is a heterogeneous group involving more t...
Development and validation of a biology-based novel therapeutic agent targeting the LIN28/ <i>let-7</i> pathway in cancer.
3114 Background: Currently, brain tumors that are diagnosed in infants and young children carry an exceptionally high risk for treatment resistance and to...
Efficacy and safety of Sapylin versus dexamethasone atomized inhalation for CCRT-induced oral mucositis in patients with nasopharyngeal carcinoma: A randomized, parallel design, and non-inferiority clinical trial.
6075 Background: Radiation-induced oral mucositis (RIOM) is a common adverse reaction to radiotherapy and chemotherapy in patients with nasopharyngeal car...
Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)–naive patients (pts) with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial.
6512 Background: In the phase 3 COMMANDS trial (NCT03682536), LUSPA was superior in improving red blood cell (RBC)-TI ≥12 wks with concurrent hemoglobin i...
Trends and gaps in colorectal cancer screening research in the Arab world: A 16-year bibliometric analysis (2007-2023).
e15701 Background: Colorectal cancer (CRC) is a significant public health concern, ranking as the third most common cancer globally and the second leading...
Novel <i>MAML2</i> fusions as oncogenic drivers in human malignancy.
e15067 Background: Our group previously identified the oncogenic fusion CRTC1::MAML2 , arising from t(11;19) translocations in muc...
Unpacking the relationship between cancer survival and political environment in the United States (US).
11030 Background: Several studies have reported on how health outcomes may differ by the political majority of a county. It is unclear the extent to which...